Capital raised by NRX Pharmaceuticals
1 Form D filing · first filed Jan 2025 · Wilmington, DE
Chief Financial Officer
Signatory on NRX Pharmaceuticals's Form D filings · $3.5M raised across 1
Michael Abrams is on file as Chief Financial Officer at NRX Pharmaceuticals in Wilmington, DE. NRX Pharmaceuticals has 1 Form D filing on record, $3.5M raised in total. Michael Abrams appears as a signatory on the company's filings.
NRX-101 is an oral, fixed-dose combination therapy that incorporates D-cycloserine and lurasidone. It is specifically being developed for the treatment of suicidal bipolar depression and has received the esteemed FDA Breakthrough Therapy designation, which indicates its potential to offer significant improvements over existing treatment options.
